Loading
PTEN is the brake on the PI3K growth pathway; when a tumour loses it the pathway runs unchecked, which is why PTEN loss now selects patients for the AKT inhibitor capivasertib. This dossier gathers the 0 products (0 approved), 5 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
PTEN loss raises PIP3 and constitutively activates AKT and mTOR; it also has nuclear roles in genome stability, so PTEN-null tumours accumulate further damage.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Prostate cancer | 12-41% | Deep deletion, and inactivating mutation on top of it | cBioPortal deep deletion: 85 of 489, 17.4%, in prad_tcga_pan_can_atlas_2018; 50 of 333, 15.0%, in prad_tcga_pub; 124 of 1,013, 12.2%, in prad_p1000; 61 of 424, 14.4%, in prad_mcspc_mskcc_2020; 262 of 2,260, 11.6%, in prostate_msk_2024; 209 of 1,465, 14.3%, in prad_cdk12_mskcc_2020; 114 of 444, 25.7%, in prad_su2c_2019; 41 of 150, 27.3%, in prad_su2c_2015; 55 of 149, 36.9%, in prad_fhcrc; 25 of 61, 41.0%, in prad_mich. Inactivating mutation adds 3 to 11% on top (182 of 2,260, 8.1%, in prostate_msk_2024; 46 of 424, 10.8%, in prad_mcspc_mskcc_2020). | cBioPortal (TCGA) |
| Triple-negative breast cancer | 12-35% | Mutation or deletion (loss) | PTEN mutation or loss in 35% of basal-like tumours, with INPP4B loss in 30% (Cancer Genome Atlas 2012); cBioPortal: deep deletion in 25 of 119, 21.0%, and mutation in 8 of 123, 6.5%, in brca_tcga_pan_can_atlas_2018; mutation in 18 of 299, 6.0%, and deep deletion in 16 of 320, 5.0%, in brca_metabric; mutation in 15 of 176, 8.5%, and deep deletion in 10 of 176, 5.7%, in breast_msk_2018. PTEN alterations (mutation or one- or two-copy deletion) in 29% of 62 metastatic TNBC patients treated with checkpoint inhibitors, where they went with a 6% versus 48% response rate (Barroso-Sousa 2020, Clin Cancer Res). | doi.org |
| Colorectal cancer | 6-8% | Inactivating mutation or deep deletion | cBioPortal: mutation in 446 of 7,237, 6.2%, plus deep deletion in 70, in crc_msk_2026; 68 of 1,134, 6.0%, plus 19 deletions, in crc_msk_2017; 34 of 534, 6.4%, plus 17 deletions of 592, in coadread_tcga_pan_can_atlas_2018; 51 of 619, 8.2%, in coadread_dfci_2016. PTEN mutation prevalence differs by side and by precise location (Loree 2018). | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Active | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclitaxel vs Placebo+Paclitaxel as First-line Treatment for Patients With Locally Advanced (Inoperable) or Metastatic TNBC. | Overall survival 17.7 vs 18.0 months (HR 0.92, p 0.32) overall and 20.4 vs 20.4 months (HR 1.05) in PIK3CA/AKT1/PTEN-altered tumours; PFS 5.6 vs 5.1 months (HR 0.72). | ||
IPATunity130 NCT03337724 | 3 | Negative | PIK3CA, AKT1 or PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer, no prior chemotherapy for advanced disease: first-line paclitaxel with ipatasertib or placebo (cohort A), 30 countries including the United Kingdom | PFS 7.4 vs 6.1 months (HR 1.02, 0.71 to 1.45); OS 24.4 vs 24.9 months (HR 1.08). Negative. | |
IMbassador250 NCT03016312 | 3 | Negative | Metastatic castration-resistant prostate cancer that had progressed on abiraterone: atezolizumab with enzalutamide against enzalutamide alone, open-label, with overall survival as the primary endpoint | Overall survival not improved: stratified hazard ratio 1.12 (95 percent confidence interval 0.91 to 1.37, p=0.28) for atezolizumab with enzalutamide against enzalutamide alone. | |
PAKT NCT02423603 | 2 | Positive | Untreated metastatic triple-negative breast cancer: first-line paclitaxel with capivasertib or placebo, UK-led academic phase 2 at 30 UK hospitals and sites in France, Georgia, Hungary, Romania and South Korea | PFS 5.9 vs 4.2 months (HR 0.74); OS 19.1 vs 12.6 months (HR 0.61, p 0.04); PIK3CA/AKT1/PTEN-altered PFS 9.3 vs 3.7 months (HR 0.30). Not confirmed by CAPItello-290. | |
LOTUS NCT02162719 | 2 | Positive | Untreated inoperable locally advanced or metastatic triple-negative breast cancer: first-line paclitaxel with ipatasertib or placebo, 44 hospitals in eight countries | PFS 6.2 vs 4.9 months (HR 0.60, p 0.037); PTEN-low 6.2 vs 3.7 months (HR 0.59, p 0.18). Not confirmed by IPATunity130. |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"PTEN" OR ABSTRACT:"PTEN" OR TITLE:"phosphatase and tensin homolog" OR ABSTRACT:"phosphatase and tensin homolog" OR TITLE:"MMAC1" OR ABSTRACT:"MMAC1" OR TITLE:"TEP1" OR ABSTRACT:"TEP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTEN, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/pten.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/pten.json. Licence CC BY-NC 4.0.